Miromatrix Medical Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey James Ross
- Full Time Employees
- 76
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6455 Flying Cloud Drive Eden Prairie MN United States of America 55344
- IPO Date
- Jun 24, 2021
- CIK
- 0001527096
- Website
- miromatrix.com
- Similar Companies
- Business
- Miromatrix Medical Inc., a biotechnology company and subsidiary of United Therapeutics Corp, develops novel technology for bioengineering fully transplantable human organs using a proprietary platform of perfusion decellularization and recellularization that removes porcine cells from pig organs and repopulates them with human cells; its lead development programs include mirokidney for end-stage renal disease, miroliverELAP for acute liver failure and miroliver for end-stage liver disease, with the platform applicable to other organs such as hearts, lungs and pancreas. The company targets patients on transplant waitlists, operating primarily in the regenerative medicine and xenotransplantation segments with research collaborations including Baxter, CareDx, Mayo Clinic, Mount Sinai Hospital and Texas Heart Institute. Founded in 2009 and headquartered in Eden Prairie, Minnesota, Miromatrix Medical underwent a major strategic shift in December 2023 when United Therapeutics completed its acquisition for approximately $91 million plus a contingent $1.75 per share tied to mirokidney clinical milestones by December 31, 2025, expanding its organ manufacturing capabilities alongside ex-vivo lung perfusion, 3D bioprinting and regenerative medicine initiatives.
United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger
United Therapeutics and Miromatrix Medical Announce Successful Tender Offer
MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO
MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO
Shareholder Alert: Ademi LLP investigates whether Miromatrix Medical Inc. has obtained a Fair Price in its transaction with United Therapeutics
Miromatrix Medical climbs 225% following $140m United Therapeutics bid
Why Is Miromatrix Medical (MIRO) Stock Up 235% Today?
MIRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Miromatrix Medical Inc. Is Fair to Shareholders
Miromatrix Medical stock soars after it agrees to be bought by United Therapeutics
United Therapeutics to Acquire Miromatrix Medical
United Therapeutics to Acquire Miromatrix Medical
Miromatrix to Present at the 2023 ISODP Organ Donation Congress
Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Mesa
Miromatrix Announces Participation in H.C. Wainwright Global Investment Conference
Miromatrix Announces Participation in the ARM Tissue Engineering and Therapeutics Workshop
Miromatrix Medical Inc. (MIRO) Q2 2023 Earnings Call Transcript
Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update
Miromatrix to Report Second Quarter 2023 Financial Results
Miromatrix Poster Voted Best in Congress at the 2023 American Transplant Congress; Jack Lake Wins Lifetime Achievement Award
Miromatrix Announces Participation in the 20th Annual Craig-Hallum Institutional Investor Conference